ReviewJournal of stem cells & regenerative medicine2025
Recent trend on sarcoma stem cell reprogramming towards study of disease progression: A systematic review.
Review in Journal of stem cells & regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoma refers to a broad type of cancer characterised by the abnormal growth of cells in connective tissues, bone, muscle, and cartilage. Although relatively rare, the survival rate of sarcoma patients is low primarily due to delayed diagnosis or metastasis at first presentation. Highly metastatic sarcoma has been suggested to be attributable to the presence of cancer stem cells (CSCs). Although a minor cell population, the stemness property renders CSCs stem cell-like characteristics. Nevertheless, CSCs presented a promising target towards advances in sarcoma therapy, particularly through stem cell reprogramming. Thus, this systematic review aims to gather existing studies on the methods of stem cell reprogramming that best produce sarcoma cancer stem cells (CSCs), which are crucial for understanding disease progression. An extensive literature search was conducted across four databases: PubMed, Wiley Online Library, Scopus, and ScienceDirect. The data obtained were synthesized and reported according to the following variables: types of cancer cells used for cancer stem cell generation, vector used for delivery of pluripotent genes, and CSCs maintenance medium. This systematic review demonstrated that cell dedifferentiation was independent of the cell sources. Furthermore, the addition of growth factors such as bFGF, EGF, or FGF significantly enhanced the formation of CSCs' spheroids. Most of the studies included in the review utilized a non-viral vector for the delivery of pluripotent gene markers into the cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.